MGNX Overview

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is3.00 USD with a low forecast of 2.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MacroGenics Inc revenue for the last quarter amounts to 41.23M USD, increased 113.03

MacroGenics Inc. EPS for the last quarter amounts to -0.22 USD, decreased -12.00

MacroGenics Inc (MGNX) has 293 emplpoyees as of May 12 2026.

Today MGNX has the market capitalization of 187.50M USD.